Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement. “Deepa’s history assisting companies in financings, partnerships, and corporate strategy will be invaluable as we advance our therapies into clinical trials, and we are thrilled to have her on our team.”
Prasad has more than 20 years of expertise in finance and operations.
“I am truly excited to be joining Secretome at this pivotal time in the company’s history. I believe that secretomes represent a true breakthrough in the field of cell-based therapy, and I look forward to helping Secretome transform the way we treat diseases,” Prasad said in a statement.
Most recently, she was president and CEO of vTv Therapeutics where she refocused operations, secured the launching of research, and helped raise $35 million in financing. Before that, Prasad was general partner at WestRiver Group where she led healthcare investments in many companies, including Design Therapeutics.
Prasad has also held leadership positions at numerous public and private companies, including Blue Shield, Optum, and Coherus Biosciences. She began her career in biotech investment banking executing private placements and buy-side/sell-side M&A.
She serves on the board of directors at Design Therapeutics and as executive director of the Robinson Life Sciences, Business and Entrepreneurship Program at UC Berkeley.
Secretome Therapeutics’ lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and the company’s pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.